Advisory Services Network’s Allogene Therapeutics ALLO Stock Holding History

Advisory Services Network’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-148	Closed	-$361	–	2245
2026 Q1	$361	Buy	+148	New	+$297	﹤0.01%	4476
2025 Q4	–	Sell	-4,069	Closed	-$5.05K	–	1880
2025 Q3	$5.05K	Buy	+4,069	New	+$4.85K	﹤0.01%	3537
2024 Q1	–	Sell	-960	Closed	-$3.08K	–	1516
2023 Q4	$3.08K	Buy	+960	New	+$2.72K	﹤0.01%	3275
2023 Q2	–	Sell	-148	Closed	-$731	–	1498
2023 Q1	$731	Hold	148	–	–	﹤0.01%	3668
2022 Q4	$931	Buy	+148	New	+$1.37K	﹤0.01%	3603
2021 Q3	–	Sell	-3,900	Closed	-$102K	–	1446
2021 Q2	$102K	Buy	+3,900	New	+$111K	﹤0.01%	1597
2020 Q4	–	Sell	-5	Closed	–	–	3272
2020 Q3	$0	Buy	+5	New	+$189	﹤0.01%	3532

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Advisory Services Network's ALLO Position: Q2 2026 in Review

Advisory Services Network sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 148 shares — an estimated $361 sold.

Advisory Services Network first reported a position in ALLO in Q3 2020 and held it in 7 quarters. The position peaked at $102K in Q2 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Advisory Services Network reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 148 Allogene Therapeutics shares in Q2 2026, an estimated $361.
Advisory Services Network first reported a position in Allogene Therapeutics in Q3 2020 and held it in 7 quarters.
Advisory Services Network's Allogene Therapeutics position peaked at $102K in Q2 2021.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.